Censa appoints new VP of Regulatory Affairs, Associate VP of Clinical Operations and Director of Quality
WELLESLEY, MA – July 19, 2018 – Censa Pharmaceuticals Inc. announced it has appointed Geoff Fatzinger PhD as Vice President of Regulatory Affairs, Michelle Skupien as Associate Vice President of Clinical Operations, and Eric Moore as Director or Quality.
Geoff joined Censa with 15+ years’ experience in regulatory affairs. Prior to joining the Censa team he held senior positions in Regulatory and Quality with early-stage biotech, CROs and large pharma including Vice President of Global Medical & Regulatory Affairs with Cmed Clinical Services.
Michelle has over 25 years of clinical development experience in clinical operations and medical marketing and prior to joining Censa she held the position of Clinical Science Operations Project Leader and Director of Clinical Research with Genzyme/Sanofi.
Eric has over 25 years of experience in the pharmaceutical, biotech and medical device industries across all phases of development, including commercial products and prior to joining Censa he held Associated Director of Quality positions with Imugen, Axcella Health and First Light Biosciences.
“I am very pleased to welcome Geoff, Michelle and Eric to the Censa management team. As we continue to develop our clinical programs, their experience and knowledge will be invaluable” said Jonathan Reis, President and CEO of Censa.
About Censa Pharmaceuticals
Censa Pharmaceuticals Inc., headquartered in Wellesley, MA, is developing medicines to improve the lives of patients with debilitating diseases. Censa’s lead product, CNSA-001, targets orphan metabolic and central nervous system diseases.
For more information, visit www.censapharma.com.